Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06057519
Other study ID # PORT- 01
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 16, 2024
Est. completion date December 31, 2025

Study information

Verified date May 2023
Source Radboud University Medical Center
Contact Jodie Schilkdraut, PhD
Phone +31 629677680
Email Jodie.schildkraut@radboudumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare an optimized dose (1800 mg) of rifampicin to standard dose (450 mg if patient <50 kg and 600 mg if patient >50kg) of rifampicin in tuberculosis patients. The main questions it aims to answer are: - To compare the incidence of hepatotoxicity occurs in the optimized dose vs standard dose arm - To compare any adverse events occur in the optimized dose vs standard dose arm - To compare final treatment outcome at the end of treatment according to WHO definitions of cure in the optimized dose regimen versus the standard dose regimen. - To compare two and three months culture conversion rates in the optimized dose regimen versus the standard dose regimen. - To describe and compare the steady-state plasma pharmacokinetics of the optimized dose regimen versus the standard dose regimen. Participants will be given an optimized dose of 1800 mg of rifampicin daily. Researchers will compare the optimized and standard dose to see if more hepatotoxicity occurs.


Recruitment information / eligibility

Status Recruiting
Enrollment 164
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The patient has provided informed consent for study participation prior to all trial-related procedures. - The patient has a diagnosis of pulmonary tuberculosis according to the local diagnostic criteria. - The patient is aged 18 years or older at the day of informed consent. - No known allergic reactions or toxicity to rifampicin in the past. - Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practice an effective method of birth control during the study. And they should not be lactating during the trial (female participants of childbearing potential only). Effective birth control for female patients has to include two methods, including methods that the patient's sexual partner(s) use. At least one must be a barrier method. Female patients are considered not to be of childbearing potential if they are post-menopausal with no menses for the last 12 months, or surgically sterile (this condition is fulfilled by bilateral oophorectomy, hysterectomy, and by tubal ligation which is done at least 12 months prior to enrolment). - The patient will be compliant to the study schedule, in the discretion of the investigator. Exclusion Criteria: - The patient has tuberculosis which is assessed to receive high dose rifampicin according to the local standard of care. - The patient started current TB treatment more than 4 weeks ago. - The patient has TB meningitis. - The patient is in a coma. - Circumstances that raise doubt about free, uncoerced consent to study participation (e.g. in a prisoner or mentally handicapped person) - The patient is not able to give consent personally. - Poor general condition or comorbidities where delay in treatment cannot be tolerated or death within three months is likely. Or if there is concurrent treatment that may interfere. - The patient is pregnant or breast-feeding. - Patient infected with a rifampicin-resistant strain of M. tuberculosis. - Known allergy or intolerance for rifamycins. - The participant has a known or suspected, current alcohol or drug or amphetamine abuse, that is, in the opinion of the investigator, sufficient to compromise the safety or cooperation of the patient. - The patient has a known allergy or intolerance, or concomitant disorders or conditions for which rifamycins or other standard TB treatment drugs are contraindicated. - The patient has had treatment with any other investigational drug within 1 month prior to enrolment, or enrolment into other clinical (intervention) trials is planned in the upcoming 6 months - Laboratory: at screening one or more of the following abnormalities were observed for the patient in screening laboratory: - Serum amino aspartate transferase (AST) and/or serum alanine aminotransferase (ALT) activity >3x the upper limit of normal - Serum total bilirubin level >2.5 times the upper limit of normal - Creatinine clearance (CrCl) level lower than 30 mls/min - Acute or severe or life-threatening liver disease induced by drugs in the past - The patient has a chronic disorder such as liver disease or renal disease. - The patient has icterus. - Previous anti-TB treatment: the patient ended a previous TB treatment (episode) within last 3 months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Optimised dose rifampicin
Optimized dose of rifampicin
Standard dose rifampicin
Standard dose rifampicin

Locations

Country Name City State
Netherlands Radboud University Medical Centre Nijmegen

Sponsors (1)

Lead Sponsor Collaborator
Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of hepatotoxicity How often does hepatotoxicity occur in patients with optimized dose rifampicin vs standard dose rifampicin 26 weeks
Secondary Adverse events The proportion of adverse events overall and graded by severity assessed to be related or probably related to rifampicin will be compared between treatment arms. 26 weeks
Secondary Treatment outcome Final treatment outcome at the end of treatment according to WHO definitions of cure will be compared between treatment arms 26 weeks
Secondary Culture conversion rate Two and three months culture conversion rates will be compared between treatment arms. 2 and 3 months post-treatment initiation
Secondary PK parameter, AUC0-24 Steady-state plasma pharmacokinetic parameters will be compared between treatment arms. The AUC0-24 will be determined using sparse PK sampling. 2 Weeks
Secondary PK parameter, Cmax Steady-state plasma pharmacokinetic parameters will be compared between treatment arms. The maximum concentration will be determined using sparse PK sampling. 2 Weeks
Secondary PK parameter, Tmax Steady-state plasma pharmacokinetic parameters will be compared between treatment arms. The time to maximum concentration will be determined using sparse PK sampling. 2 Weeks
Secondary PK parameter, Clearance Steady-state plasma pharmacokinetic parameters will be compared between treatment arms. The clearance of rifampicin will be determined using sparse PK sampling. 2 Weeks
Secondary PK parameter, Volume of distribution Steady-state plasma pharmacokinetic parameters will be compared between treatment arms. The volume of distribution of rifampicin will be determined using sparse PK sampling. 2 Weeks
Secondary PK parameter, T1/2 Steady-state plasma pharmacokinetic parameters will be compared between treatment arms. The half life of rifampicin will be determined using sparse PK sampling. 2 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06084715 - The INSTITUT Study
Terminated NCT03028129 - Prevention of Tuberculosis in Prisons Phase 4
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Withdrawn NCT03862248 - Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More Phase 3
Completed NCT03271567 - Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Active, not recruiting NCT04919239 - Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB) Phase 2
Active, not recruiting NCT03251196 - TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
Recruiting NCT05926466 - BTZ-043 Dose Evaluation in Combination and Selection Phase 2
Recruiting NCT04752592 - Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Not yet recruiting NCT04968886 - TuBerculosis Viability Interregional Study and Agreement on Biological Tests
Not yet recruiting NCT04485156 - Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) Phase 3
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT01364324 - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Active, not recruiting NCT04179500 - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers Phase 2
Completed NCT05899400 - A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
Completed NCT04938596 - Airborne Preventive Measures to Reduce New TB Infections in Household Contacts N/A
Recruiting NCT05455112 - Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis Phase 2
Completed NCT03044158 - GeneXpert Performance Evaluation for Linkage to Tuberculosis Care N/A